Sponsored by
How 2M+ Professionals Stay Ahead on AI
AI is moving fast and most people are falling behind.
The Rundown AI keeps you ahead of the curve.
It's a free AI newsletter that keeps you up-to-date on the latest AI news, and teaches you how to apply it in just 5 minutes a day.
Plus, complete the quiz after signing up and they’ll recommend the best AI tools, guides, and courses — tailored to your needs.
Firefly Neuroscience (AIFF)
Firefly Neuroscience (NASDAQ: AIFF) is today’s standout small-cap stock in the news, following a major partnership announcement that sent shares soaring over 60% last week and keeping the stock in focus.
Why It’s in the News
FDA-Cleared ADHD Treatment Partnership
On September 25, 2026, Firefly announced a strategic partnership with NeuroSigma to expand access to the Monarch eTNS® System, the first FDA-cleared, non-drug treatment for pediatric ADHD in children ages 7–12.
Key details:
What it does: Monarch is a palm-sized, prescription-only device that delivers mild external trigeminal nerve stimulation (eTNS) through a forehead patch while the child sleeps.
Who it’s for: Children 7–12 with ADHD who are not currently on prescription ADHD medication
Firefly’s role: Firefly will introduce Monarch to its nationwide network of clinicians using its FDA 510(k)-cleared Evoke™ brain-function assessment platform, supporting clinician education and adoption.
Market context: A 2024 study found nearly one-third of the ~6.5 million U.S. children with ADHD receive no ADHD-specific treatment, highlighting a large untreated population.
NeuroSigma began U.S. sales of its second-generation Monarch device in July 2026 after building a waitlist of over 1,500 patients, caregivers, and providers.
Stock Performance & Profile
Market cap: ~$200–$250 million (small-cap territory)
Recent move: AIFF jumped ~70% on the partnership news (Sept 25) and has remained elevated in subsequent sessions.
Business: Firefly develops AI-powered EEG/ERP brain analytics and biomarkers, with its Evoke System used for objective brain-function assessment.
Catalyst pipeline: In March 2026, Firefly reported discovery of EEG/ERP biomarkers that may help differentiate among three ADHD presentation.
What to Watch
Adoption metrics: How quickly clinicians in Firefly’s network begin prescribing Monarch.
Revenue traction: NeuroSigma’s specialty pharmacy fulfillment and any future revenue-sharing disclosures.
Research updates: Further validation of Firefly’s ADHD biomarker findings could add speculative upside.
Risks to Consider
Small-cap volatility: AIFF is a highly speculative, low-float name prone to sharp moves.
Execution risk: Partnership success depends on clinician uptake and real-world prescribing, not just the announcement.
Dilution/burn: Like many micro-cap biotech/medtech firms, future capital raises are possible.
Bottom line: Firefly Neuroscience is today’s small-cap “stock of the day” thanks to a clinically meaningful, FDA-cleared ADHD treatment partnership that addresses a large untreated patient population—and the market is reacting accordingly.
Not investment advice. Do your own due diligence.
Until next time, keep compounding …
Disclaimer: The information provided on this website is for educational and informational purposes only and does not constitute financial, investment, or trading advice. Investing in securities involves risk, including the potential loss of principal; always conduct your own research and consult a qualified financial professional before making investment decisions.
